From Genome to Drugs: New Approaches in Antimicrobial Discovery

dc.creatorSerral, Federico
dc.creatorCastello, Florencia A.
dc.creatorSosa, Ezequiel J.
dc.creatorPardo, Agustín M.
dc.creatorPalumbo, Miranda Clara
dc.creatorModenutti, Carlos
dc.creatorPalomino, María Mercedes
dc.creatorLazarowski, Alberto
dc.creatorAuzmendi, Jerónimo
dc.creatorRamos, Pablo Ivan P.
dc.creatorNicolás, Marisa F.
dc.creatorTurjanski, Adrián G.
dc.creatorMartí, Marcelo A.
dc.creatorPorto, Darío Fernández do
dc.date2021-08-17T11:03:26Z
dc.date2021-08-17T11:03:26Z
dc.date2021
dc.date.accessioned2023-09-26T20:53:50Z
dc.date.available2023-09-26T20:53:50Z
dc.identifierSERRAL, Federico et al. From Genome to Drugs: New Approaches in Antimicrobial Discovery. Frontiers in Pharmacology, 2021.
dc.identifier1663-9812
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/48638
dc.identifier10.3389/fphar.2021.647060
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8865786
dc.descriptionCNPq (process no. 306894/ 2019-0) and granted by CAPES (process no. 88887.368759/
dc.descriptionDecades of successful use of antibiotics is currently challenged by the emergence of increasingly resistant bacterial strains. Novel drugs are urgently required but, in a scenario where private investment in the development of new antimicrobials is declining, efforts to combat drug-resistant infections become a worldwide public health problem. Reasons behind unsuccessful new antimicrobial development projects range from inadequate selection of the molecular targets to a lack of innovation. In this context, increasingly available omics data for multiple pathogens has created new drug discovery and development opportunities to fight infectious diseases. Identification of an appropriate molecular target is currently accepted as a critical step of the drug discovery process. Here, we review how diverse layers of multi-omics data in conjunction with structural/ functional analysis and systems biology can be used to prioritize the best candidate proteins. Once the target is selected, virtual screening can be used as a robust methodology to explore molecular scaffolds that could act as inhibitors, guiding the development of new drug lead compounds. This review focuses on how the advent of omics and the development and application of bioinformatics strategies conduct a “bigdata era” that improves target selection and lead compound identification in a costeffective and shortened timeline.
dc.formatapplication/pdf
dc.languageeng
dc.publisherFrontiers Media
dc.rightsopen access
dc.subjectDescoberta de drogas
dc.subjectAntibacterianos
dc.subjectDoenças transmissíveis
dc.subjectInvestimentos em Saúde
dc.subjectBiologia computacional
dc.subjectdrug discovery,
dc.subjectDrug target
dc.subjectMetabolic reconstruction
dc.subjectStructural modeling
dc.subjectTarget prioritization
dc.subjectVirtual screening
dc.titleFrom Genome to Drugs: New Approaches in Antimicrobial Discovery
dc.typeArticle


Este ítem pertenece a la siguiente institución